BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BioCentury | Apr 10, 2019
Tools & Techniques

Microbiome makes its mark outside the gut

Microbiome makes its mark outside the gut The gut microbiome wasn’t the only population of bacteria under the spotlight at this year’s American Association for Cancer Research (AACR) meeting. A growing focus was on the...
BioCentury | Apr 24, 2018
Distillery Therapeutics


INDICATION: Prostate cancer Cell culture studies suggest CAR T cell therapies targeting CEACAM5 could help treat neuroendocrine prostate cancer. Bioinformatics analysis of 7,555 human cell surface proteins, and transcriptomic and proteomic analyses of eight human...
BioCentury | Apr 23, 2018
Preclinical News

CAR T against cell surface proteins to treat prostate cancer

Researchers at University of California Los Angeles identified cell surface targets to treat prostate adenocarcinoma and neuroendocrine prostate cancer, two distinct major subtypes of advanced prostate cancer, and suggested that CAR T cell therapy against...
BioCentury | Jun 2, 2017
Company News

Sanofi, Immunogen amend financials of ADC deals

In exchange for $30 million, ImmunoGen Inc. (NASDAQ:IMGN) and Sanofi (Euronext:SAN; NYSE:SNY) eliminated potential milestone and royalties payments the biotech was eligible to receive under two deals involving five compounds. The candidates are isatuximab, SAR408701...
BioCentury | Mar 29, 2017
Clinical News

CM-24: Ph I terminated

Merck terminated an open-label, dose-escalation, U.S. and Israeli Phase I trial evaluating CM-24 in combination with Keytruda pembrolizumab in 27 patients. The company said CM-24 showed no signs of efficacy in the trial and that...
BioCentury | Mar 23, 2017
Clinical News

Merck ends development of cCAM compound

Merck & Co. Inc. (NYSE:MRK) terminated development of oncology candidate CM-24 , spokesperson Pamela Eisele told BioCentury. Eisele said the mAb showed no signs of efficacy in a dose-ranging Phase I study in combination with Keytruda...
BioCentury | Mar 3, 2017
Company News

National Research Council Canada, Helix deal

NRC granted Helix worldwide rights to compound 2A3 for cancer indications. The license grants Helix the right to use the antibody in multiple systems, including CAR T cells , in combination with conjugates of the biotech's...
BioCentury | Aug 4, 2016
Product R&D

Antibiotic wisdom

While one of the biggest problems in infectious diseases is the overuse of antibiotics, few point-of-care tools are available to help physicians decide when and what to prescribe. Focusing on host genes rather than microbial...
Items per page:
1 - 10 of 54